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Abstract  
 
The antidiabetic potential of thirteen novel dogfish glucagon derived analogues were assessed in 
vitro and in acute in vivo studies.  Stable peptide analogues enhanced insulin secretion from 
BRIN-BD11 β-cells (p<0.001) and reduced acute glycaemic responses following intraperitoneal 
glucose (25 nmol/kg) in healthy NIH Swiss mice (p<0.05-p<0.001).  The in vitro insulinotropic 
actions of [S2a]dogfish glucagon, [S2a]dogfish glucagon-exendin-4(31-39) and [S2a]dogfish 
glucagon-Lys30-γ-glutamyl-PAL, were blocked (p<0.05-p<0.001) by the specific GLP-1 and 
glucagon receptor antagonists, exendin-4(9-39) and (desHis1Pro4Glu9)glucagon amide but not by 
(Pro3)GIP, indicating lack of GIP receptor involvement.  These analogues dose-dependently 
stimulated cAMP production in GLP-1 and glucagon (p<0.05-p<0.001) but not GIP-receptor 
transfected cells. They improved acute glycaemic and insulinotropic responses in high-fat fed 
diabetic mice and in wild-type C57BL/6J and GIPR-KO mice (p<0.05-p<0.001), but not GLP-
1R-KO mice, confirming action on GLP-1 but not GIP receptors.  Overall, dogfish glucagon 
analogues have potential for diabetes therapy, exerting beneficial metabolic effects via GLP-1 
and glucagon receptors.  
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Introduction  
Since the start of the twenty first century there has been an explosion of interest in the use of   
stable incretin peptides (mimetics) for type 2 diabetes (T2DM) therapy (Holst 2004; Campbell & 
Drucker 2013; Irwin & Flatt 2015; Nauck 2015).  These injectable agents based upon the 
structure of human GLP-1 have multiple antidiabetic actions, including promotion of postprandial 
glucose-induced insulin secretion, suppression of glucagon secretion, reduction in gastric 
emptying, augmentation of glucose uptake in tissues and, at least in animal models, potential 
benefits on pancreatic β-cell growth and regeneration (Drucker 2013; Campbell & Drucker 
2013).  Incretin mimetics such as exendin-4 (Byetta) and the acylated GLP-1 analogue, liraglutide 
(Victoza) showed promising clinical efficacy in early human trials (Madsbad 2009; Nikfar et al. 
2012; Kela & Davies 2012; Wysham et al. 2013; McCormack 2014; Scott 2014) and are now 
widely used in clinical practice.  Nevertheless, the use of single therapeutic agents to overcome 
the many challenges of posed by obesity and T2DM have been quite disappointing (Sadry & 
Drucker 2013).  As a result, there is growing interest in the use of dual or co-agonist peptides 
which could enhance multiple metabolic pathways and provide better treatments options (Claus et 
al. 2007; Tom et al. 2007; Franklin et al. 2011; Bhat et al. 2013a, 2013b; Fosgerau et al. 2013; 
Trevaskis et al. 2013; Finan et al. 2013; Skarbaliene et al. 2015; Irwin & Flatt 2015; Irwin et al. 
2015). 
 In addition to the widely accepted classical counter regulatory role for glucagon in 
combatting hypoglycaemia through promoting hepatic glucose output (Ramnanan et al. 2011), 
this hormone has many extrahepatic actions, including stimulation of insulin secretion, lipolysis 
and energy expenditure (Gelling et al., 2003; Sadry & Drucker 2013; Charron & Vuguin 2015; 
Ye at al. 2015). Interestingly, both the glucagon receptor (GCGR) and GLP-1 receptor (GLP-1R) 
are members of the class B G-protein-coupled receptor superfamily but have opposing 
mechanisms of action in glucose homeostasis.  However, because activation of both receptors 
induces satiety, co-agonist peptide analogues with optimal ratios of GLP-1 to glucagon agonism 
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may exert synergistically superior effects on body weight, glycaemic control and lipid 
metabolism (Sadry & Drucker 2013).  Furthermore, a study by Pocai and colleagues (2009) 
testing GLP-1/glucagon dual-agonists found that normalisation of glycaemic control, as well as 
significant weight loss, was more impressive in diet-induced obese (DIO) mice treated with the 
dual agonist than treatment with a GLP-1R selective agonist alone.  In another study (Tan et al., 
2013), GLP-1/glucagon co-agonism improved resting energy expenditure in non-diabetic, DIO 
mice, and it was inferred that the dual activation of these receptors would have beneficial effects 
in terms of glycaemic control and lipid metabolism in humans with T2DM.  Day et al. (2009) 
reported that full agonism of the GLP-1 receptor in combination with a certain degree of 
glucagon agonism normalises glycaemic levels and enhances body fat reduction in obese rodents.  
Design of the best GLP-1R to glucagon ratio is difficult to predict and research in this respect is 
currently lacking.   
 Over the past 15 years, we have developed a strong interest in examining the potential of 
synthetic and naturally occurring peptides which have structural similarities with incretin 
hormones and glucagon in an attempt to uncover and test novel approaches to diabetes and 
obesity therapy (Irwin & Flatt 2015).  The elasmobranchs, represented in the present day by 
sharks, dogfishes, rays and skates represent the first vertebrates in evolution to develop a pancreas 
containing the four kinds of islet hormone cells (β, α, δ, and PP) found in mammals (Falkmer and 
Van Noorden 1983). Glucagon has been isolated from the intestine of the European common 
dogfish Scyliorhinus canicula (Elasmobranchi) (Conlon et al. 1987 and the peptide is of 
particular interest because it exhibits structural similarities with human GLP-1, GIP and glucagon 
(Table 1). Comparison of the primary structures indicates that dogfish glucagon shares three 
amino acid residues (Glu3, Tyr13, and Lys20) with human GLP-1 that are not found in human 
glucagon.  This led us to the hypothesis that dogfish glucagon may represent a template for the 
design of new antidiabetic peptides that may possess multiple agonist activity.  In the present 
paper we report the insulin-releasing and anti-hyperglycaemic activities of dogfish glucagon and 
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analogues designed to exhibit stability to and extended bioactivity in vivo (Table 1). We have 
looked at their effects using clonal beta cells, incretin and glucagon receptor transfected cells, 
specific receptor antagonists and GLP-1 and GIP receptor knockout mice.  Furthermore, acute 
actions on glucose homeostasis and insulin release were examined in lean and high-fat fed mice 
with glucose intolerance and insulin resistance (Winzell and Ahren, 2004).  
 
Materials & Methods  
 
Peptides. Table 1 displays the amino acid sequences of dogfish glucagon, dogfish glucagon 
analogues, exendin-4(1-39) and the human peptides used. Preliminary studies indicated that 
dogfish glucagon was cleaved in plasma at positions 2, 7, 12, 13 and 21 producing smaller 
fragment peptides. The basic structure of dogfish glucagon was modified at each of these 
positions including substitution of a D-Ala for Ser at position 2 (i.e. [S2a]), in an attempt to 
confer improved enzyme resistance.  In addition, we added extended C-terminus of dogfish 
glucagon with the last 9 amino acid residues of exendin-4(1-39) (P-S-S-G-A-P-P-P-S-amide) to 
produce [S2a]dogfish glucagon-exendin-4(31-39) in order to help stabilize the peptide and 
improve its ability to interact with the GLP-1 receptor. Finally, a gamma-glutamyl spacer with 
palmitate adjunct was added to the side-chains of the lysine residues at positions 12, 20, or 30 to 
promote albumin binding and extend in vivo bioactivity as previously reported for stable forms of 
GLP-1 and GIP (Green et al. 2004; Irwin et al. 2005; O’Harte et al. 2007; Kerr et al. 2009; 
Lennox et al. 2013; Pathak et al. 2015).  Mammalian (human) forms of GLP-1, GIP, glucagon, 
[S2a]GIP, [S2s]glucagon, [S2a]GLP-1, (Pro3)GIP and desHis1Pro4Glu9-glucagon amide and 
exendin-4(9-39) were also used in some of the tests as indicated in the text.  All peptides were 
purchased from EZBiolabs (Carmel, IL, USA; greater than 95% purity).  In addition to QC data 
supplied, all peptides were checked for purity and their molecular mass was confirmed using in-
house matrix assisted laser desorption ionization-time of flight mass spectrometry (MALDI-ToF 
MS) as described previously (Gault et al. 2011). 
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Plasma degradation assay.  Peptides (20 µg) were incubated at 37°C in 50 mmol/L TEA-HCl 
(pH 7.8) with pooled mouse plasma in order to test their enzymatic stability.  Degradation 
profiles were obtained using RP-HPLC analysis as described previously (Gault et al. 2011) and 
HPLC peak area data were used to calculate percentage intact peptide remaining after 8 h 
incubation. 
 
In vitro insulin secretion. Effects of peptides on in vitro insulin secretion were examined using 
clonal rat BRIN-BD11 beta cells. The generation and characteristics of this cell line have been 
reported previously (McClenaghan et al. 1996). Briefly, BRIN-BD11 cells were seeded (150,000 
cells per well) into 24-well plates (Nunc, Roskilde, Denmark) and allowed to attach overnight at 
37°C. Following 40 min pre-incubation (1.1 mmol/L glucose; 37oC), cells were incubated (20 
min; 37°C) in the presence of 5.6 and 16.7 mmol/L glucose with a range of peptide 
concentrations (10-12 to 10-6 mol/L). Insulin secretion was also measured in the presence of 
specific receptor antagonists including exendin-4(9-39), (Pro3)GIP and desHis1Pro4Glu9-glucagon 
amide which block GLP-1, GIP and glucagon receptors, respectively (Green et al. 2005; Parker et 
al. 2007; O’Harte et al. 2013).  After 20 min incubation, buffer was removed from each well and 
aliquots (200 µl) stored at -20°C prior to determination of insulin by radioimmunoassay (Flatt & 
Bailey 1981).  
 
In vitro cAMP production. Effects of dogfish glucagon analogues as well as exendin-4, GLP-1, 
GIP and glucagon on cellular cAMP production were assessed in Chinese Hamster Lung (CHL) 
cells transfected with either the human GIP- or GLP-1-R, as well as human embryonic kidney 
(HEK293) cells transfected with the human glucagon-R (Bhat et al. 2013b). The generation and 
properties of these cells have been reported previously (Thorens et al. 1993; Gremlich et al. 
1995). Cells were seeded (200,000 cells per well) into 96-well plates (Nunc) and washed with 
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Hank’s Balanced Salt Solution (HBSS) buffer before incubation with test peptides (10−6 to 
10−12 mol/L) in the presence of 200 µmol/l 3-isobutyl-1-methylxanthine (IBMX) for 20 min at 
37°C. After incubation, medium was removed and cells lysed before measurement of cAMP 
using Parameter cAMP assay (R&D Systems, Abingdon, UK) according to the manufacturer’s 
instructions (Hogan et al. 2011). 
 
Animals. Acute animal studies were carried out in male NIH Swiss mice (Harlan Ltd., 
Blackthorne, UK; 8 to 20 weeks old), and in C57BL/6 mice with genetic deletion of either of the 
incretin receptors GIP-R or GLP-1R.  The background and generation of GIP-R and GLP-1R 
have been previously described (Scrocchi et al. 1996; Miyawaki et al. 1999). Acute experiments 
were also performed in NIH Swiss TO mice previously fed a high-fat diet for 100 days composed 
of 45% fat, 20% protein and 35% carbohydrate (total energy 26.15 KJ/g; Special Diet Services, 
Essex, UK).  Animals were housed in a 12:12 h light/dark cycle and had free access to drinking 
water and food. All animal experiments were conducted according to UK Home Office 
Regulations (UK Animals Scientific Procedures Act 1986) and the “Principles of Laboratory 
Animal Care” (NIH Publication Number 86-23, revised 1985). No adverse effects were observed 
following administration of any of the peptides. 
 
Acute actions of peptides on plasma glucose and insulin concentrations in vivo. Plasma glucose 
and insulin responses were evaluated after intraperitoneal (i.p.) injection of glucose alone (18 
mmol/kg body weight) or in combination with test peptides (25 nmol/kg body weight) in normal 
and DIO mice. In a separate series of experiments, plasma glucose and insulin responses were 
evaluated after i.p. injection of glucose alone (18 mmol/kg body weight) at 0 h or 4 h after an i.p. 
injection of dogfish glucagon or related analogues, glucagon, GLP-1 or exendin-4 (all at 25 
nmol/kg body weight) in normal lean Swiss TO mice or DIO mice. All test solutions were 
administered in a final volume of 8 ml/kg body weight. 
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Acute effect of dogfish glucagon and its analogues on plasma glucose and insulin in vivo with 
C57BL/6J control, GIPr-KO and GLP-1r-KO mice 
For better understanding of receptor specificity of dogfish glucagon and its analogues C57BL/6J 
wild-type, GIPr-KO and GLP-1r-KO mice were used.  Mice received an i.p. injection of glucose 
alone (18 mmol/kg body weight), or combined with either dogfish glucagon, dogfish glucagon 
analogues or exendin-4(1-39) (all at 25 nmol/kg body weight). Blood glucose and plasma insulin 
was measured at times 0, 15, 30, 60, 90 and 120 min.  
 
Biochemical analyses. Blood samples were collected from the cut tip on the tail vein of conscious 
mice into chilled fluoride/heparin glucose micro-centrifuge tubes (Sarstedt, Numbrecht, 
Germany) at the time points indicated in the Figures. Samples were immediately centrifuged 
using a Beckman microcentrifuge (Beckman Instruments, Galway, Ireland) for 1 min at 13,000 x 
g. Plasma glucose was assayed by an automated glucose oxidase procedure using a Beckman 
Glucose Analyzer II (Beckman Instruments, Galway, Ireland). Plasma insulin was assayed by a 
modified dextran-coated charcoal RIA (Flatt & Bailey 1981). 
 
Statistical analysis. Results are expressed as means ± SEM and data compared using the unpaired 
Student’s t-test. Where appropriate, data were compared using repeated measures ANOVA or 
one-way ANOVA, followed by the Student-Newman-Keuls post-hoc test.  Incremental area 
under the curve (AUC) analyses for plasma glucose and insulin were calculated using GraphPad 
Prism version 5.0.  EC50 values were calculated from sigmoidal dose-response data using 
GraphPad Prism version 5.0. Groups of data were considered to be significantly different if 
P<0.05. 
 
Results 
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Stability of peptides in plasma.  
Following exposure of dogfish glucagon to mouse plasma, various fragment peptides including 
14-29, 1-17, 1-22 were identified by a combination of HPLC and MS analysis (data not shown).  
Since we were aware that His-Ala is rapidly removed by DPP-4 in the case of GLP-1 and we 
were interested in testing Ala in the penultimate position we made additional modifications at this 
position within the analogues tested (Table 1).  Dogfish glucagon and all analogues were 
degraded to varying degrees when incubated with mouse plasma for 8 h (data not shown).  
Preliminary data indicated that substitution of the Ser2 residue in native dogfish glucagon (39% 
degraded after 8 h) by D-Ala, or by 2-aminoisobutyric acid (Aib) or 2-aminoisobutyric acid 
(Abu) (Table 1) showed no significant improvement in the rate of peptide degradation.  However, 
peptides that contained a D-Ala2 substitution together with either a C-terminal extension by 
exendin-4(31-39) or a palmitate coupled via a γ-glutamyl linker to the ε-amino group of the Lys30 
residue showed enhanced stability in plasma at 8 h (18% and 12% degraded, respectively).  In 
contrast, the derivatives containing an acylated modification at Lys20 or at position Lys12, did not 
show increased resistance to cleavage by plasma peptidases with 34% and 38% degraded after 8 
h, respectively. 
 
In vitro insulin secretion.  Table 2 displays the effects of dogfish glucagon and related analogues 
on insulin secretion in BRIN-BD11 cells. All peptides (10-10 to 10-6 mol/l), significantly 
(P<0.001) increased insulin secretion compared to 5.6 mmol/l glucose control.  A range of insulin 
secretory potencies were observed (Table 2) with [S2a][S2a]dogfish glucagon, [S2a][S2a]dogfish 
glucagon-exendin-4(31-39), and [S2a]dogfish glucagon-Lys30-γ-glutamyl-PAL exhibiting 
impressive insulinotropic actions (P<0.05 to P<0.01) when compared to the native dogfish 
glucagon (Table 2; Fig. 1). The effects observed were at least comparable with the insulinotropic 
actions of equimolar GLP-1 and more efficacious than either human glucagon or GIP (Fig. 1). 
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Acute glucose-lowering and insulinotropic actions of dogfish glucagon peptide analogues in lean 
and high-fat fed mice.  
The acute in vivo effects of dogfish glucagon, dogfish glucagon analogues and human glucagon 
on glucose homeostasis were studied in normal healthy NIH Swiss mice (Fig. 2 and Table 2). 
Intraperitoneal injection of glucagon (25 nmol/kg body weight) together with glucose (18 
mmol/kg/body weight) resulted in a significant increase (p<0.05) in plasma glucose concentration 
at 60 min post injection compared to mice receiving glucose alone (Fig. 2A).  Consistent with 
this, plasma glucose area under the curve (AUC) was also increased (p<0.05) (Fig. 2A).  In 
contrast, dogfish glucagon, [S2a]dogfish glucagon, and [S2a]glucagon-exendin-4(31-39) 
effectively lowered blood glucose (AUC0-120 min, p<0.001) when compared with glucose alone 
(Fig. 2A). This anti-hyperglycaemic action was reflected in the enhanced insulinotropic response 
produced by the same analogues (Fig. 2B; (p<0.01 to p<0.001). Plasma glucose and insulin AUC 
data for all dogfish peptides are shown in Table 2. Analogues modified at position 2 and C-
terminally modified analogues of dogfish glucagon are identified as being amongst the most 
effective. The effects observed, including EC50 and Emax values, were at least comparable with 
the insulinotropic actions of equimolar GLP-1 and more efficacious than either human glucagon 
or GIP (Fig. 1). On the basis of these data together with measures of stability in plasma and 
insulin-releasing activity (Tables 1 and 2), dogfish glucagon (control) together with [S2a]dogfish 
glucagon, [S2a]dogfish glucagon-exendin-4(9-39), and [S2a]dogfish glucagon-Lys30-γ-glutamyl-
PAL were carried forward for further evaluation. 
Although [S2a]dogfish glucagon-Lys30-γ-glutamyl-PAL showed no appreciable effect on 
both plasma glucose and plasma insulin in the acute in vivo tests (Fig. 2A and Fig. 2B), the 
acylated peptide showed enhanced anti-hyperglycaemic and insulinotropic actions when a 4 h 
delay was incorporated into the ipGTT (Fig. 3A and Fig. 3B).  Dogfish glucagon, [S2a]dogfish 
glucagon, and [S2a]dogfish glucagon-exendin-4(31-39) also displayed significant glucose 
lowering and insulinotropic capabilities (Fig. 3A and Fig. 3B).   
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Feeding a high fat diet for 16 weeks resulted in progressive body weight gain (54.6 ± 2.6 
vs. 47.0 ± 2.7 g; P<0.01) and non-fasting hyperglycemia (8.6 ± 1.2 vs. 4.6 ± 0.3 mmol/l; P<0.05) 
compared with age-matched controls on normal laboratory chow (data not shown).  When 
glucose tolerance tests were performed in the high-fat fed mice, neither dogfish glucagon nor 
[S2a]dogfish glucagon-Lys30-γ-glutamyl-PAL reduced the glycaemic excursion compared to mice 
given glucose alone (Fig. 4A).  In contrast, the dogfish glucagon analogues [S2a]dogfish 
glucagon and [S2a]dogfish glucagon-exendin-4(31-39) reduced the plasma glucose excursion 
(Fig. 4A, AUC0-120 min, p<0.05 to p<0.001).  However, dogfish glucagon and all analogues tested 
did enhance the overall insulinotropic response (Fig. 4B, p<0.05 to p<0.001).  These effects were 
equivalent to those observed with human GLP-1 or exendin-4(1-39) (Fig.4B). 
 
Measurement of intracellular cAMP in GIP, GLP-1 transfected cell lines and HEK293SGnT1-
cells 
To gain insight into the receptors mediating the actions of dogfish glucagon and its analogues, 
their ability to stimulate cAMP production was investigated using GLP-1, GIP and glucagon 
receptor transfected cells (Fig. 5). A significant and dose-dependent increase (p<0.05 to p<0.001) 
in intracellular cAMP was observed in GLP-1 and glucagon receptor transfected cells (Fig. 5A 
and Fig. 5C).  The actions were broadly equivalent to those of human GLP-1 or glucagon with 
approximately similar EC50 and Emax values. This pattern contrasted sharply with the cAMP 
response observed with GIP receptor transfected cells where no stimulation of intracellular 
messenger was detected (Fig. 5B).   These data suggest that dogfish glucagon and related 
analogues operate through activation of the GLP-1 and glucagon receptors but not via the GIP 
receptor. 
  
Effect of dogfish glucagon and dogfish glucagon analogues on insulin secretion from BRIN-BD11 
cells in the presence of specific receptor antagonists.  
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To assess further the mechanism of action, insulinotropic effects of dogfish glucagon and the 
chosen 3 analogues at a concentration of 10-7 M were investigated using BRIN-BD11 cells in the 
absence and presence of various receptor antagonists. These included exendin-4(9-39), (Pro3)GIP 
and (desHis1Pro4Glu9)glucagon amide (peptide O) which block GLP-1, GIP and glucagon 
mediated actions, respectively.  None of the three antagonist peptides tested had any effect on 
insulin secretion when tested alone (Fig. 6).  The established secretagogue alanine (10 mM) was 
used as positive control. All dogfish glucagon-related peptides significantly stimulated insulin 
release (p<0.001).  Exendin-4(9-39) (10-6 M and 10-7 M) consistently abolished dogfish glucagon-
stimulated insulin release (p<0.05 – p<0.001) (Fig. 6A-D).  The glucagon receptor antagonist 
Peptide O ((desHis1Pro4Glu9)glucagon amide) also inhibited insulin release by [S2a]dogfish 
glucagon (p<0.05 – p<0.01) (Fig. 6B), [S2a]dogfish glucagon-exendin-4(31-39) (p<0.05) (Fig. 
6C), and [S2a]dogfish glucagon-Lys30-γ-glutamyl-PAL (p<0.01) compared to results obtained for 
dogfish glucagon analogues in the absence of this antagonist (Fig. 6D).  In contrast, (Pro3)GIP 
failed to inhibit the insulin release produced by the various dogfish glucagon analogues (Fig. 6A-
D), further confirming that these peptides did not operate via the GIP receptor. 
 
Acute effect of dogfish glucagon and dogfish glucagon analogues on plasma glucose and insulin 
in vivo using incretin receptor knockout mice 
Possible involvement of GLP-1 and GIP receptors in mediating in vivo actions of dogfish 
glucagon and analogues was examined using wild-type C57BL/6 mice and corresponding incretin 
receptor KO mice (Fig. 7).  When injected acutely together with glucose (18 mmol/kg) in wild-
type controls, dogfish glucagon, [S2a]dogfish glucagon, [S2a]dogfish glucagon-exendin-4(31-39) 
and [S2a]dogfish glucagon-Lys30-γ-glutamyl-PAL significantly decreased plasma glucose 
concentrations at 30 min and 60 min (p<0.05 - p<0.01). The integrated plasma glucose 
concentration (AUC0-120 min) was also significantly lowered (p<0.001) compared with glucose 
alone (Fig. 7A) and this was reflected in an enhanced insulinotropic response (Fig. 7B).  A 
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similar pattern was observed in GIPr-KO mice (Fig. 7A and Fig. 7B) but not in GLP-1 KO mice 
(Fig. 7A and Fig. 7B).  From these results, it is concluded that dogfish glucagon and the three 
analogues selected operate through the GLP-1 receptor but not the GIP receptor thereby 
confirming the findings from the in vitro cell studies using specific incretin receptor antagonists. 
 
Discussion 
Multiple-acting co-agonist peptides represent novel therapeutic agents which could be beneficial 
in the ongoing fight against the growing global health challenge of T2DM, obesity and related 
metabolic diseases (Sadry and Drucker, 2013; Pocai et al., 2009).  In this study, we examined 
insulin secretory and metabolic responses to dogfish glucagon which we hypothesized might 
replicate actions of glucagon together with other important members of the glucagon-secretin 
family of peptides (Kopin et al. 1991; Inagaki et al. 1996). Indeed, dogfish glucagon shares 52%, 
55% and 83% structural identity with human GIP, GLP-1 and glucagon, respectively.  From an 
evolutionary perspective, it has been suggested that the glucagon sequence first arose 
approximately 1000 million years ago (MYA) while GLP-1 and GLP-2 diverged from each other 
approximately 700 MYA (Irwin et al. 1999).   The physiological roles of the proglucagon-derived 
peptides in the ancient fishes such as the dogfish have not been investigated but, in teleosts, the 
responsiveness of hepatocytes to glucagon is limited to high concentrations, while physiological 
concentrations of GLP-1 effectively regulate hepatic metabolism.  In contrast to mammals, GLP-
1 shows very weak insulinotropic activity in teleosts (Plisetskaya and Mommsen, 1996). 
Mammalian glucagon is subjected to rapid degradation in vivo by dipeptidyl peptidase-4 
(DPP-4), with cleavage of Ser2-Gln3 (producing the major fragment glucagon 3-29), followed by 
further removal of the following dipeptide (producing glucagon 5-29) (Hinke et al. 2000; 
Pospisilik et al. 2001) as well as by neutral endopeptidase 24.11 (Trebbien et al., 2004).  Short 
half-life is a problem for potential therapeutic peptides (Ahren 2004; Werle and Bernkop-
Schnürch 2006) and to circumvent this difficulty, we designed a series of dogfish glucagon 
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analogues modified at positions 2, 13, 21 (Table 1) in order to confer peptidase resistance (Werle 
and Bernkop-Schnürch 2006). As expected native dogfish glucagon was degraded in plasma and 
several of the structural modifications made afforded significant resistance to degradation in 
vitro. In particular, we synthesized two daughter analogues of [S2a]dogfish glucagon with C-
terminal extension using the last 9 C-terminal amino acids of exendin-4 and other analogues with 
acylation at Lys12, Lys20 or Lys30.  The latter is a well-established approach to extend in vivo 
bioactivity through enhanced binding to albumin in blood (Kurtzhals et al. 1995; Holz & 
Chepurny 2003), whereas the former is thought to enhance the peptide’s affinity for the GLP-1 
receptor (Al-Sabah and Donnelly, 2003).  These peptides exhibited the lowest rates of 
degradation observed presumably due to protein binding resulting in steric hindrance at target 
sites of plasma enzymes as well as the enhanced ability of the peptide to self-associate in solution 
in a manner similar to liraglutide (Knudsen 2004). 
Dogfish glucagon and all analogues tested stimulated insulin release from clonal BRIN-
BD11 cells. Whereas the native peptide was slightly less potent than equimolar concentrations of 
human glucagon, GLP-1 and GIP, the analogues [S2a]dogfish glucagon, [S2a]dogfish glucagon-
exendin-4(31-39) and [S2a]dogfish glucagon(Lys30)PAL exhibited greater potency and efficacy 
than one or more of these human peptides as indicated by EC50 and Emax values. Similarly, the 
native form and each of the modified dogfish glucagon peptides demonstrated significant glucose 
lowering and insulin-releasing activity during glucose tolerance tests in normal mice. This was in 
marked contrast to human glucagon which was hyperglycaemic and only prompted a small rise in 
circulating insulin concentrations.  This response is consistent with its counter regulatory role in 
mammals whereas in teleost fish plasma concentrations of GLP-1 are higher than those of 
glucagon and both GLP-1 and glucagon exert similar effects on glucose metabolism (Plisetskaya 
and Mommsen, 1996).  [S2a]dogfish glucagon, [S2a]dogfish glucagon-exendin-(31-39) and 
[S2a]glucagon(Lys30)PAL were again amongst the most active peptides in lean mice and 
subsequent studies demonstrated that their effect persisted for at least 4 h post injection.  This 
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suggests the success of strategies employed to confer enzymatic stability and extend in vivo 
bioactivity as also observed for stable incretin peptide hormones (Holz & Chepurny 2003; 
Knusen 2004).  In the high-fat fed mouse model of obesity-diabetes (Surwit et al. 1988), dogfish 
glucagon lacked glucose lowering ability despite a small increase of insulin. This presumably 
reflect the insulin resistance in this model (Turner et al. 2013). However, the three analogues of 
dogfish glucagon tested here exhibited anti-hyperglycaemic effects similar to GLP-1 or exendin-4 
in high-fat fed mice.  
From these observations, it appears that dogfish glucagon does not operate in a manner 
analogous to mammalian glucagon when administered to mice. The action profile more resembles 
that of oxyntomodulin which is a naturally occurring C-terminally extended glucagon molecule 
known to activate both glucagon and GLP-1 receptors (Pocai 2012; Irwin & Flatt 2015).  Dogfish 
glucagon, like human glucagon, has 29 amino acid residues so there is not a great similarity in C-
terminal structure compared with oxyntomodulin itself.  However, when native dogfish glucagon 
and the three lead analogues were tested on cells transfected with human receptors for glucagon 
or GLP-1, cyclic AMP production was enhanced as was observed with the native human peptide 
with broadly similar EC50 and Emax values.  In contrast, no activity was observed in GIPR 
transfected cells.  This receptor specificity was confirmed by blockade of in vitro insulinotropic 
activity by established antagonists of GLP-1 and glucagon but not by an antagonist of GIP.  
Furthermore, the peptides exhibited anti-hyperglycaemic and insulinotropic effects in GIPR KO 
mice, whereas these actions were abolished in mice without functional GLP-1 receptors. The 
results of the present study showing that dogfish glucagon operates through both glucagon and 
GLP-1 mediated pathways in mammals thereby offers a possible new candidate molecule for 
T2DM treatment by co-agonistic action.  Evidence has been obtained from preclinical studies to 
support a positive role for glucagon acting as a satiety factor, increasing resting energy 
expenditure and promoting lipolysis in adipose tissue (Habegger et al., 2010). As highlighted in 
recent years, GLP-1 has many physiological actions which can help ameliorate diabetes, 
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including reduction of food intake, slowing of gastric emptying, promotion of glucose uptake in 
peripheral tissues, inhibition of glucagon release and stimulation of glucose dependent insulin 
secretion and enhancement of pancreatic β-cell function (Campbell & Drucker, 2013). Further 
long-term studies in animal models of diabetes are required to test effectiveness of long-acting 
dogfish glucagon analogues in animal models and whether the above and any other actions can 
afford new and improved therapeutic options. 
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Legends to Figures 
Figure 1. Effects of dogfish glucagon (A), [S2a]dogfish glucagon (B), [S2a]dogfish glucagon-
exendin-4(31-39) (C) and [S2a]dogfish glucagon-Lys30-γ-glutamyl-PAL (D) on insulin release 
from BRIN-BD11 cells. Values are mean ± SEM for n=8 for insulin release. *p<0.05, **p<0.01 
and ***p<0.001 compared to 5.6 mM glucose alone. +p<0.05, ++p<0.01 and +++p<0.001 
compared to 10-7 M dogfish glucagon, [S2a]dogfish glucagon, [S2a]dogfish glucagon-exendin-
4(31-39) or [S2a]dogfish glucagon-Lys30-γ-glutamyl-PAL in parallel A-D, respectively. 
 
Figure 2. Effects of dogfish glucagon, [S2a]dogfish glucagon, [S2a]dogfish glucagon –exendin-
4(31-39) and [S2a]dogfish glucagon-Lys30-γ-glutamyl-PAL on plasma glucose (A) and insulin 
response (B) in lean mice. Blood glucose and plasma insulin were measured before and after 
intraperitoneal administration of glucose (18 mmol/kg body weight) alone or in combination with 
glucagon, dogfish glucagon, [S2a]dogfish glucagon, [S2a]dogfish glucagon-exendin-4(31-39) or 
[S2a]dogfish glucagon-Lys30-γ-glutamyl-PAL (each at 25 nmol/kg body weight). Integrated 
blood glucose (B) and plasma insulin (D) area under the curve (AUC0-120 min) values are also 
included. Values represent mean ± SEM for 8 mice. *p<0.05, **p<0.01 and ***p<0.001 
compared to glucose alone. ++p<0.01 and +++p<0.001 compared to glucagon treated mice. 
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Figure 3. Acute effects of dogfish glucagon, [S2a]dogfish glucagon, [S2a]dogfish glucagon-
exendin-4(31-39) and [S2a]dogfish glucagon-Lys30-γ-glutamyl-PAL on blood glucose (A) and 
insulin response (B) in lean mice, 4 h post injection. Blood glucose and plasma insulin were 
measured after a glucose load (18 mmol/kg body weight) 4 hours after intraperitoneal 
administration of saline, dogfish glucagon, [S2a]dogfish glucagon, [S2a]dogfish glucagon-
exendin-4(31-39) or [S2a]dogfish glucagon-Lys30-γ-glutamyl-PAL (each at 25 nmol/kg body 
weight). Integrated blood glucose (B) and plasma insulin (D) (area under the curve, AUC) 
responses are also included. Values represent mean ± SEM for 8 mice.  *p<0.05 and **p<0.01 
compared to saline. 
 
Figure 4. Effects of dogfish glucagon, [S2a]dogfish glucagon, [S2a]dogfish glucagon-exendin-
4(31-39) and [S2a]dogfish glucagon-Lys30-γ-glutamyl-PAL on blood glucose (A) and insulin 
response (C) in high fat fed mice.  Plasma glucose and insulin were measured before and after 
intraperitoneal administration of glucose (18 mmol/kg body weight) alone or in combination with 
dogfish glucagon, [S2a]dogfish glucagon, [S2a]dogfish glucagon-exendin-4(31-39), [S2a]dogfish 
glucagon-Lys30-γ-glutamyl-PAL, GLP-1 or exendin-4 (each at 25 nmol/kg body weight). 
Integrated blood glucose (B) and plasma insulin (D) (area under the curve, AUC) responses are 
also included. Values represent mean ± SEM for 8 mice. *p<0.05, **p<0.01 and ***p<0.001 
compared to glucose alone.  
 
Figure 5. Effects of dogfish glucagon and related peptides on intracellular cAMP production in 
Chinese hamster lung cells transfected with human GLP-1 (A), GIP (B) and glucagon (C) 
receptors. Intracellular cAMP was measured from GLP-1, GIP or glucagon receptor transfected 
cells exposed to dogfish glucagon and related peptides (10
-9
 to 10
-6
 M) for 60 min. EC50 values 
are shown for peptides with significant effects on cAMP production. Values are mean ± SEM for 
n=8. *p<0.05, **p<0.01 and ***p<0.001 compared to none (control).  
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Figure 6. Effects of 10-7 M dogfish glucagon (A), [S2a]dogfish glucagon (B), [S2a]dogfish 
glucagon-exendin-4(31-39) (C) and [S2a]dogfish glucagon-Lys30-γ-glutamyl-PAL (D) in the 
presence of different antagonists, exendin-4(9-39), (Pro3)GIP and peptide O 
((desHis1Pro4Glu9)glucagon amide) on insulin secretion from BRIN-BD11 cells. Values are mean 
± SEM for n=8 for insulin release. *p<0.05, **p<0.01 and ***p<0.001 compared to 5.6 mM 
glucose alone. +p<0.05, ++p<0.01 and +++p<0.001 compared to 10-7 M (A) dogfish glucagon, 
(B) [S2a]dogfish glucagon, (C) [S2a]dogfish glucagon-exendin-4(31-39) or (D) [S2a]dogfish 
glucagon-Lys30-γ-glutamyl-PAL. 
 
 
Figure 7. Acute effects of dogfish glucagon, [S2a]dogfish glucagon,  [S2a]dogfish glucagon-
exendin-4(31-39) and [S2a]dogfish glucagon-Lys30-γ-glutamyl-PAL on plasma glucose (A) and 
insulin responses (B) in C57BL/6J mice, GIPr-KO mice or GLP-1r-KO mice. Blood glucose and 
plasma insulin were measured prior to and after intraperitoneal administration of glucose (18 
mmol/kg body weight) alone or in combination with dogfish glucagon, [S2a]dogfish glucagon, 
[S2a]dogfish glucagon-exendin-4(31-39), [S2a]dogfish glucagon-Lys30-γ-glutamyl-PAL or 
exendin-4 (each at 25 nmol/kg body weight). Integrated blood glucose and plasma insulin (area 
under the curve, AUC) responses are also included. Values represent mean ± SEM for 8 mice. 
*p<0.05, **p<0.01 and ***p<0.001 compared to glucose alone. +p<0.05 and ++p<0.01 
compared to exendin-4. ∆p<0.05, ∆∆p<0.01 and ∆∆∆p<0.001 compared with dogfish glucagon. 
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TABLE 1 Primary structures and molecular masses of dogfish glucagon and related peptides  
Name Amino acid sequence Theoretical molecular mass 
(Observed mass Da) 
Dogfish glucagon  
(1-29) 
H-S-E-G-T-F-T-S-D-Y-S-K-Y-M-D-N-R-R-A-K-D-F-V-Q-W-L-M-N-T 
 
3528.9 
(3528.1) 
Exendin-4 H-G-E-G-T-F-T-S-D-L-S-K-Q-M-E-E-E-A-V-R-L-F-I-E-W-L-K-N-G-G-P-S-S-G-A-P-P-P-S-amide 
 
4186.6 
(4186.3) 
GLP-1(7-36) amide H-A-E-G-T-F-T-S-D-V-S-S-Y-L-E-G-Q-A-A-K-E-F-I-A-W-L-V-K-G-R-amide 
 
3297.7 
(3296.0) 
GIP(1-30) Y-A-E-G-T-F-I-S-D-Y-S-I-A-M-D-K-I-H-Q-Q -D-F-V-N-W-L-L-A-Q-K 
 
3551.1 
(3550.9) 
Human glucagon H-S-Q-G-T-F-T-S-D-Y-S-K-Y-L-D-S-R-R-A-Q-D-F-V-Q-W-L-M-N-T 
 
3482.8 
(3481.5) 
[S2a] dogfish glucagon H-a-E-G-T-F-T-S-D-Y-S-K-Y-M-D-N-R-R-A-K-D-F-V-Q-W-L-M-N-T 
 
3512.9 
(3514.0) 
[S2Aib] dogfish glucagon H-Aib-E-G-T-F-T-S-D-Y-S-K-Y-M-D-N-R-R-A-K-D-F-V-Q-W-L-M-N-T 3527.0 
(3527.4) 
[S2Abu] dogfish glucagon H-Abu-E-G-T-F-T-S-D-Y-S-K-Y-M-D-N-R-R-A-K-D-F-V-Q-W-L-M-N-T 3527.0 
(3527.0) 
[S2a] dogfish glucagon-exendin-4(31-39) H-a -E-G-T-F-T-S-D-Y-S-K-Y-M-D-N-R-R-A-K-D-F-V-Q-W-L-M-N-T-P-S-S-G-A-P-P-P-S-amide 4289.8 
(4290.3) 
[S2a.T7I] dogfish glucagon H-a -E-G-T-F-I-S-D-Y-S-K-Y-M-D-N-R-R-A-K- -F-V-Q-W-L-M-N-T 3525.0 
(3525.0) 
[S2a,K12I] dogfish glucagon H-a -E-G-T-F-T-S-D-Y-S-I-Y-M-D-N-R-R-A-K-D-F-V-Q-W-L-M-N-T 
 
3497.9 
(3496.0) 
[S2a,Y13A] dogfish glucagon H-a -E-G-T-F-T-S-D-Y-S-K-A-M-D-N-R-R-A-K-D-F-V-Q-W-L-M-N-T 
 
3420.8 
(3418.6) 
[S2a,Y13y] dogfish glucagon H-a -E-G-T-F-T-S-D-Y-S-K-y-M-D-N-R-R-A-K-D-F-V-Q-W-L-M-N-T 3512.9 
(3513.4) 
[S2aD21d] dogfish glucagon H-a -E-G-T-F-T-S-D-Y-S-K-Y-M-D-N-R-R-A-K-d-F-V-Q-W-L-M-N-T 3512.9 
(3513.6) 
[S2a] dogfish glucagon-Lys
12
-γ-glutamyl-PAL H-a -E-G-T-F-T-S-D-Y-S-K-Y-M-D-N-R-R-A-K-D-F-V-Q-W-L-M-N-T  
                                           -γ-Glutamyl–PAL 
3779.3 
(3780.7) 
[S2a] dogfish glucagon-Lys
20
-γ-glutamyl-PAL H- a -E-G-T-F-T-S-D-Y-S-K-Y-M-D-N-R-R-A-K-D-F-V-Q-W-L-M-N-T  
                                                                           -γ-Glutamyl–PAL 
3880.5 
(3881.5) 
[S2a] dogfish glucagon-Lys
30
-γ-glutamyl-PAL H-a -E-G-T-F-T-S-D-Y-S-K-Y-M-D-N-R-R-A-K-D-F-V-Q-W-L-M-N-T-K-γ-Glutamyl–PAL 4008.7 
(4009.1) 
              PAL = palmitate 
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TABLE 2 In vitro insulin secretory activity and in vivo glucose lowering and insulin releasing actions of dogfish glucagon and related analogues 
Peptide  
(10
-7
 M) 
In vitro insulin secretion In vivo responses 
EC50 
(M) 
5.6 mM glucose 
(ng/10
6
 cells/20 min) 
Plasma glucose 
AUC0-60min (mmol/l.min) 
Plasma insulin 
AUC0-60min (ng/ml.min) 
    
None (glucose alone) -               1.010±0.0+                 641.9±27.6                  13.3±1.1 
Human glucagon - 3.140±0.2***  757.4±38.1*                  12.2±1.2 
Dogfish glucagon (1-29) 8.6620e-008 3.329±0.6***              365.8±61.7***+++           20.32±2.59**++ 
[S2a] dogfish glucagon 1.5740e-008      5.875±1.4***++              290.6±51.5***+++                 33.72±12.5***+++ 
[S2Aib] dogfish glucagon 3.9010e-008 4.278±0.8***              263.7±32.2***+++               27.77±6.4***+++ 
[S2Abu] dogfish glucagon 7.4080e-008    5.336±1.0***+ 629.4±119.2     17.58±3.0*+ 
[S2a] dogfish glucagon-exendin-4(31-39) 1.2350e-008       4.191±0.5***++               215.0±21.8***+++                46.97±12.5***+++ 
[S2a,T7I) dogfish glucagon 2.5460e-010   1.807±0.2*** 598.8±85.5 11.28±2.9 
(S2a,K12I) dogfish glucagon 1.3760e-007   2.601±0.7***              451.4±126.3**+++     18.58±3.9*+ 
[S2a,Y13a] dogfish glucagon 3.0780e-008        4.163±0.5***++      573.8±69.8++ 14.30±3.0 
[S2a,Y13y] dogfish glucagon 7.6970e-007   1.990±0.5***      541.8±122.4++   17.72±4.1+ 
[S2a.D21d] dogfish glucagon 2.5260e-008   3.088±0.3***                 526.2±165.4+   16.63±2.0+ 
[S2a] dogfish glucagon-Lys
12
-γ-glutamyl-PAL 9.6230e-008   2.823±0.6***        579.8±49.9*++ 16.25±2.2 
[S2a] dogfish glucagon-Lys
20
-γ-glutamyl-PAL 2.7530e-008   2.422±0.7***    614.3±35.0+ 15.62±4.0 
[S2a] dogfish glucagon-Lys
30
-γ-glutamyl-PAL 6.8510e-008     3.825±0.5***+ 654.8±44.0 15.00±3.7 
Values for in vitro insulin secretion and in vivo responses are mean ± SEM for n=8. *p<0.05, **p<0.01 and ***p<0.001 compared to 5.6 mM glucose control. 
+p<0.05, ++p<0.01 and +++p<0.001 compared to human glucagon. EC50 values are shown together with responses at 10
-7 
M peptide. Integrated glycaemic 
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and insulin (area under the curve, AUC) responses to peptides (25 nmol/kg body weight) are shown following i.p. administration to normal mice together 
with 18 mmol/kg glucose.  
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Highlights: 
• Dual agonist activity recognised in dogfish glucagon analogues 
• Dogfish glucagon analogues operate through GLP-1 and glucagon receptors 
• Peptide analogues improve glycaemic control in diet induced obese diabetic mice 
